115 related articles for article (PubMed ID: 38587027)
1. miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.
Sun Z; Ren M; Niu J; Tang G; Li Y; Kong F; Song X
Environ Toxicol; 2024 Apr; ():. PubMed ID: 38587027
[TBL] [Abstract][Full Text] [Related]
2. MiR-29b-3p Reverses Cisplatin Resistance by Targeting COL1A1 in Non-Small-Cell Lung Cancer A549/DDP Cells.
Jia R; Wang C
Cancer Manag Res; 2020; 12():2559-2566. PubMed ID: 32368137
[TBL] [Abstract][Full Text] [Related]
3. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
4. Exosomal miR-338-3p suppresses non-small-cell lung cancer cells metastasis by inhibiting CHL1 through the MAPK signaling pathway.
Tian W; Yang X; Yang H; Lv M; Sun X; Zhou B
Cell Death Dis; 2021 Oct; 12(11):1030. PubMed ID: 34718336
[TBL] [Abstract][Full Text] [Related]
5. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
Liu Y; Zhang Y; Li Q; Xu R; Huang N
Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
[TBL] [Abstract][Full Text] [Related]
6. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
7. MiR-139-5p Targetedly Regulates YAF2 and Mediates the AKT/P38 MAPK Signaling Pathway to Alleviate the Metastasis of Non-Small Cell Lung Cancer Cells and Their Resistance Against Cisplatin.
Yan Y; Jin X; Sun H; Pang S; Kong X; Bu J; Xu S
Cancer Manag Res; 2021; 13():3639-3650. PubMed ID: 33981163
[TBL] [Abstract][Full Text] [Related]
8. LncRNA WT1-AS/miR-494-3p Regulates Cell Proliferation, Apoptosis, Migration and Invasion via PTEN/PI3K/AKT Signaling Pathway in Non-Small Cell Lung Cancer.
Wu C; Yang J; Li R; Lin X; Wu J; Wu J
Onco Targets Ther; 2021; 14():891-904. PubMed ID: 33603394
[TBL] [Abstract][Full Text] [Related]
9. miR-29b Regulates Lung Cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/AKT Pathway.
Zhang H; Wang R; Deng Q
Comput Math Methods Med; 2022; 2022():3110330. PubMed ID: 36003920
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN.
Wang H; Guan X; Tu Y; Zheng S; Long J; Li S; Qi C; Xie X; Zhang H; Zhang Y
J Exp Clin Cancer Res; 2015 Jun; 34(1):59. PubMed ID: 26063204
[TBL] [Abstract][Full Text] [Related]
11. Targeting the miR-6734-3p/ZEB2 axis hampers development of non-small cell lung cancer (NSCLC) and increases susceptibility of cancer cells to cisplatin treatment.
Wei L; Jiang J
Bioengineered; 2021 Dec; 12(1):2499-2510. PubMed ID: 34107856
[TBL] [Abstract][Full Text] [Related]
12. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
[TBL] [Abstract][Full Text] [Related]
13. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p.
Hua G; Zeng ZL; Shi YT; Chen W; He LF; Zhao GF
Pharmacology; 2021; 106(9-10):498-508. PubMed ID: 34352791
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
15. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
16. Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).
Wei D; Zeng J; Rong F; Xu Y; Wei R; Zou C
Bioengineered; 2022 Mar; 13(3):5126-5140. PubMed ID: 35170372
[TBL] [Abstract][Full Text] [Related]
17. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
[TBL] [Abstract][Full Text] [Related]
18. miR-29b-3p suppresses the malignant biological behaviors of AML cells via inhibiting NF-κB and JAK/STAT signaling pathways by targeting HuR.
Tang YJ; Wu W; Chen QQ; Liu SH; Zheng ZY; Cui ZL; Xu JP; Xue Y; Lin DH
BMC Cancer; 2022 Aug; 22(1):909. PubMed ID: 35986311
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
[TBL] [Abstract][Full Text] [Related]
20. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
